Encyclopedia of Psychopharmacology

- ABC Transporters
- Absorption
- Abstinence
- Abuse
- Abuse Liability
- Acamprosate
- BAC
- Balanced Placebo Design
- Barbital
- Barbiturates
- Basal Forebrain Cholinergic Neurons
- Behavioral Allocation Function
- Cabergoline
- Cachexia
- Caffeine
- Caffeine Withdrawal Syndrome
- Caffeinism
- cAMP
- DARPP-32
- db/db Mouse
- D-cycloserine
- Decision Making
- Declarative and Non-Declarative Memory
- Declarative Memory
- Early Ventral Hippocampal Lesion Model
- Eating and Appetite
- Eating Disorder: Anorexia Nervosa
- Eating Disorders: Animal Models
- Eating Disorders: Binge-Eating
- Echolalia
- FAA
- Face Validity
- Facial Dysmorphology
- False Memory
- False Negative
- False Positive
- G protein-Coupled Receptors
- GABA
- GABAA Receptor
- GABAergic Transmission
- Gabapentin
- Galantamine
- Habit Reversal Therapy
- Habit Reversal Training
- Habituation
- Half-Life
- Hallucinations
- Hallucinogen Abuse
- IACUC
- ICD
- Idiopathic
- Imaging Mass Spectrometry
- Imipramine
- Impairment of Functioning; Measurement Scales
- Kappa-Opioid Agonists
- Kappa-Receptor
- Keratotic Lesion
- Ketamine
- Ketamine
- Khat
- L-Alpha-Acetyl-Methadol
- Lamotrigine
- Lanreotide
- Latent Inhibition
- Latin Square Design
- Laxatives
- Magnetic Resonance Imaging
- Major and Minor and Mixed Anxiety-Depressive Disorders
- Major Tranquilizer
- Mania
- MAO-B Inhibitor
- Mass Spectrometry
- N-Acetylcysteine
- Nafion
- Naloxone
- Naltrexone
- N-Arachidonylethanolamine
- Narcolepsy
- ob/ob Mouse
- Obsessions
- Obsessive-Compulsive Anxiety Disorders
- Occasion Setting with Drugs
- Octreotide
- Off-Label Use of Drugs
- P300
- Pain
- Pain and Psychopharmacology
- Pair-Feeding
- Palatability
- Paliperidone
- qEEG
- QT Interval
- Quality of Life
- Quazepam
- Quetiapine
- Radial Arm Maze
- Radionuclide
- Radiopharmaceutical
- Radiotracer
- Randomized Controlled Trials
- Rapamycin
- Saporin
- Satiety
-

Ian Stolerman received a PhD in Psychopharmacology at University College London in 1969. This was followed by postdoctoral experience at the Albert Einstein College of Medicine (NY) and the University of California, Los Angeles. He then moved to Birmingham and became a member of the MRC Neuropharmacology Unit. In 1980 he relocated to the Institute of Psychiatry, London where he remains as a member of the MRC External Scientific Staff. He heads the Section of Behavioural Pharmacology and is co-chair of the Institute's addictions interdisciplinary research group.As part of his efforts to raise the profile of the discipline of behavioural pharmacology, Ian Stolerman was a founder of the European Behavioural Pharmacology Society and became its first chairperson in 1986. Since 1992 he has been Co-Editor of the journal Drug and Alcohol Dependence and he is now vice-President of the International Society of Addiction Journal Editors.The Drug-discrimination Database, maintained by Professor Stolerman and funded by the US National Institute on Drug Abuse is a unique research tool for both students and research professionals interested in the neurobiological bases of addiction. Ian Stolerman received a PhD in Psychopharmacology at University College London in 1969. This was followed by postdoctoral experience at the Albert Einstein College of Medicine (NY) and the University of California, Los Angeles. He then moved to Birmingham and became a member of the MRC Neuropharmacology Unit. In 1980 he relocated to the Institute of Psychiatry, London where he remains as a member of the MRC External Scientific Staff. He heads the Section of Behavioural Pharmacology and is co-chair of the Institute's addictions interdisciplinary research group.As part of his efforts to raise the profile of the discipline of behavioural pharmacology, Ian Stolerman was a founder of the European Behavioural Pharmacology Society and became its first chairperson in 1986. Since 1992 he has been Co-Editor of